Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...

Because Keytruda is an intravenous infusion and not a medicine that a person can self-administer, Medicare Part B will help pay for the drug. Part B covers medical services, including doctor’s visits, ...

Both Opdivo and Keytruda come as liquid solutions. The two drugs are given as an intravenous (IV) infusion, which is an injection into your vein given over a period of time. Infusions for both Opdivo ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global ...

(Reuters) - U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-selling ...

Adding the drug Keytruda to standard chemotherapy can extend the lives of some women with an aggressive form of breast cancer, a new study finds. The study involved women with advanced triple-negative ...